Duncan Donohue
Overview
Explore the profile of Duncan Donohue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grunberger J, Newton H, Donohue D, Dobrovolskaia M, Ghandehari H
Nanotoxicology
. 2024 Oct;
18(7):599-617.
PMID: 39460666
Immunostimulation caused by nanoparticles may be beneficial or adverse depending on their intended application. Activation of immune cells is beneficial for indications targeting the immune system for therapeutic purposes, such...
2.
Ibanez K, Donohue D, Malys T, Lee J
Sci Rep
. 2024 Jul;
14(1):17459.
PMID: 39075200
We investigated the association of CA125 response with prognosis and RECIST response/progressive disease (PD) criteria in recurrent high grade serous ovarian cancer (HGSOC) patients treated with a cell cycle checkpoint...
3.
Giudice E, Huang T, Nair J, Zurcher G, McCoy A, Nousome D, et al.
Nat Commun
. 2024 Mar;
15(1):2805.
PMID: 38555285
The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the...
4.
Swanstrom A, Gorelick R, Welker J, Schmidt F, Lu B, Wang K, et al.
EBioMedicine
. 2023 Aug;
95:104764.
PMID: 37625266
Background: Long-acting subcutaneous lenacapavir (LEN), a first-in-class HIV capsid inhibitor approved by the US FDA for the treatment of multidrug-resistant HIV-1 with twice yearly dosing, is under investigation for HIV-1...
5.
Newton H, Zhang J, Donohue D, Unnithan R, Cedrone E, Xu J, et al.
Front Allergy
. 2023 Jul;
4:1126012.
PMID: 37470031
Introduction: Immunophenotyping, which is the identification of immune cell subsets based on antigen expression, is an integral technique used to determine changes of cell composition and activation in various disease...
6.
Holley C, Cedrone E, Donohue D, Neun B, Verthelyi D, Pang E, et al.
Molecules
. 2021 Dec;
26(24).
PMID: 34946542
Understanding, predicting, and minimizing the immunogenicity of peptide-based therapeutics are of paramount importance for ensuring the safety and efficacy of these products. The so-called anti-drug antibodies (ADA) may have various...
7.
Rosati M, Terpos E, Ntanasis-Stathopoulos I, Agarwal M, Bear J, Burns R, et al.
Front Immunol
. 2021 Dec;
12:793953.
PMID: 34899762
Durability of SARS-CoV-2 Spike antibody responses after infection provides information relevant to understanding protection against COVID-19 in humans. We report the results of a sequential evaluation of anti-SARS-CoV-2 antibodies in...
8.
Thomopoulos T, Rosati M, Terpos E, Stellas D, Hu X, Karaliota S, et al.
Viruses
. 2021 Sep;
13(9).
PMID: 34578426
COVID-19 is an ongoing pandemic with high morbidity and mortality. Despite meticulous research, only dexamethasone has shown consistent mortality reduction. Convalescent plasma (CP) infusion might also develop into a safe...
9.
Rosati M, Agarwal M, Hu X, Devasundaram S, Stellas D, Chowdhury B, et al.
PLoS Pathog
. 2021 Sep;
17(9):e1009701.
PMID: 34551020
The speed of development, versatility and efficacy of mRNA-based vaccines have been amply demonstrated in the case of SARS-CoV-2. DNA vaccines represent an important alternative since they induce both humoral...
10.
Terpos E, Stellas D, Rosati M, Sergentanis T, Hu X, Politou M, et al.
Eur J Intern Med
. 2021 May;
89:87-96.
PMID: 34053848
Elucidating the characteristics of human immune response against SARS-CoV-2 is of high priority and relevant for determining vaccine strategies. We report the results of a follow-up evaluation of anti-SARS-CoV-2 antibodies...